Our Story
The future of Advanced Therapies
The Advanced Therapies Congress has hosted Europe’s largest commercially focused ATMP event in the UK for the past 18 years, and now we’re bringing our show to Boston!
What makes us different?
The Advanced Therapies Congress focuses on tackling challenges at each stage of development to accelerate development of next generation therapies to benefit patients. We bring together decision makers from key biotech and pharma companies, putting forward a good ratio of buyers and sellers in our audience.
Start-ups: our start-up village hosts early-stage companies for our audience to do business with early stage and mid stage biotech companies: a cross section of the developmental pipeline, buyers from every stage of development are present.
Networking: our networking app, Terrapinn Events App, facilitates networking for all attendees, creating a world-class environment for sponsors, speakers and guests alike.
With 8 tracks of content, the agenda covers everything from manufacturing, supply chain & logistics, pricing &market access, to developments in key therapeutic areas; cell therapy, gene therapy, gene modified cell therapy, gene editing, stem cells, regenerative medicine, and much more.
Advanced Therapies USA 2025 will feature
MISSION: To unite advanced therapies leaders from across the world, to give insight and to promote collaboration to accelerate the development & commercialisation of next generation medicines, bring them to market and help change patient lives.
200 expert speakers
8 tracks
50 sponsors
50 start-ups & 100 posters
1000+ attendees
Smart AI assisted networking
One to one meetings
More: Roundtables, panels, workshops, opportunities to meet face to face
WHY BOSTON?
Recognized globally as the Undisputed Life Science Capital, Greater Boston is the world's premier hub for biotechnology and advanced therapies. It is ideally positioned on the East Coast with unparalleled access to major domestic and international destinations.
As the epicenter of scientific innovation, the region has earned the nicknames "Genetown" and "Cellicon Valley." Massachusetts-based biopharma companies raised $18.2 billion in venture capital in 2023, representing nearly a quarter of all US life science VC funding, demonstrating the massive investment fueling growth in the Cell and Gene Therapy (CGT) sector.
Greater Boston is home to nearly 1,000 biotech companies and over 102,000 life science professionals, boasting the highest concentration of life science talent per capita globally. This thriving ecosystem is anchored by world-renowned academic powerhouses like Harvard and MIT and 24 world-class hospitals and research institutions in the Longwood Medical Area. The region received $4.1 billion in NIH funding in 2023, driving a powerful, collaborative network that accelerates the development of groundbreaking advanced therapies from lab to clinic.This dense cluster provides a comprehensive infrastructure and scientific prowess that underpins the world's leading cell and gene therapy and biopharmaceutical companies, including:
Moderna - CRISPR Therapeutics - Intellia Therapeutics - Editas Medicine - bluebird bio - 2seventy Bio - Vertex Pharmaceuticals - Takeda - Biogen - AbbVie - Sanofi - Novartis
Stay up-to-date
Join our mailing list to receive exclusive content and offers.
By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.
Get Involved with the Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events